Category Archives: Events

From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.

In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there!

Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement.

Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.

We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We are glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

Explicyte is planning a new in vivo shuttle session by mid-November that can be held on a series of syngeneic tumor mouse models. This shuttle session can focus either on only an in vivo efficacy monitoring or on a comprehensive assessment relying on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.

Explicyte was pleased to participate in the AACR Virtual Annual Meeting to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities that support drug discovery.

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.